A detailed history of Susquehanna International Group, LLP transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 53,168 shares of AVIR stock, worth $169,605. This represents 0.0% of its overall portfolio holdings.

Number of Shares
53,168
Previous 67,546 21.29%
Holding current value
$169,605
Previous $223,000 20.18%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.17 - $4.02 $45,578 - $57,799
-14,378 Reduced 21.29%
53,168 $178,000
Q2 2024

Aug 15, 2024

SELL
$3.31 - $4.04 $390,133 - $476,174
-117,865 Reduced 63.57%
67,546 $223,000
Q1 2024

May 07, 2024

BUY
$3.09 - $4.56 $408,087 - $602,225
132,067 Added 247.58%
185,411 $749,000
Q4 2023

Feb 14, 2024

SELL
$2.8 - $3.35 $460,683 - $551,175
-164,530 Reduced 75.52%
53,344 $162,000
Q3 2023

Nov 14, 2023

SELL
$3.0 - $3.79 $262,233 - $331,287
-87,411 Reduced 28.63%
217,874 $653,000
Q2 2023

Aug 11, 2023

BUY
$3.21 - $5.06 $384,647 - $606,329
119,828 Added 64.61%
305,285 $1.14 Million
Q1 2023

May 16, 2023

BUY
$3.0 - $4.97 $458,259 - $759,182
152,753 Added 467.08%
185,457 $621,000
Q4 2022

Feb 14, 2023

BUY
$4.35 - $6.17 $49,955 - $70,856
11,484 Added 54.12%
32,704 $157,000
Q3 2022

Nov 14, 2022

SELL
$5.49 - $8.79 $149,306 - $239,052
-27,196 Reduced 56.17%
21,220 $121,000
Q2 2022

Aug 15, 2022

BUY
$5.33 - $8.18 $30,951 - $47,501
5,807 Added 13.63%
48,416 $344,000
Q1 2022

May 16, 2022

BUY
$5.5 - $9.19 $173,783 - $290,376
31,597 Added 286.93%
42,609 $308,000
Q4 2021

Feb 14, 2022

SELL
$7.67 - $44.59 $516,382 - $3 Million
-67,325 Reduced 85.94%
11,012 $98,000
Q3 2021

Nov 15, 2021

BUY
$21.33 - $35.06 $1.34 Million - $2.2 Million
62,837 Added 405.4%
78,337 $2.75 Million
Q2 2021

Aug 11, 2021

BUY
$19.22 - $59.08 $297,910 - $915,740
15,500 New
15,500 $333,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $266M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.